Estrella Immunopharma (ESLA) vs Neuphoria Therapeutics (NEUP)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Estrella Immunopharma (ESLA) has outperformed Neuphoria Therapeutics (NEUP) over the past year, losing 67.9% versus a loss of 81.8%. Neuphoria Therapeutics is the larger company by market cap ($18.1 million vs $16.1 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ESLA | NEUP |
|---|---|---|
| Share price | $0.37 | $3.35 |
| Market cap | $16.09M | $18.13M |
| 1-day change | -11.38% | +0.01% |
| YTD return | -73.24% | -13.66% |
| 1-year return | -67.88% | -81.76% |
| 5-year return | -95.77% | — |
| EPS (TTM) | $-0.25 | $-3.06 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $3.15 | $19.21 |
| 52-week low | $0.3083 | $3.19 |
| Distance from 52-week high | -88.25% | -82.56% |
| Analyst consensus | none | none |
| Avg. price target upside | +3143.24% | — |
| Average volume | 38.61K | 161.66K |
| Shares outstanding | 43.50M | 5.41M |
| Employees | — | 1 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ESLA has outperformed NEUP by 13.9 percentage points over the past year.
About Estrella Immunopharma
ESLA stock →Estrella Immunopharma, Inc., a clinical-stage biopharmaceutical company, develops T-cell therapies for blood cancers and solid tumors in the United States. The company's lead product candidate is EB103, which is in Phase I/II clinical trial, for the treatment of diffuse large B-cell lymphoma; EB104, which is in pre-clinical trial, to treat diffuse large B-cell lymphoma and acute lymphocytic leukemia; and EB201, which is in pre-clinical trial, for the treatment of systemic lupus erythematosus.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances)
About Neuphoria Therapeutics
NEUP stock →Neuphoria Therapeutics Inc., a clinical stage biopharmaceutical company, develops novel allosteric ion channel modulators for patients with serious central nervous system disorders in Australia. Its lead product candidate is BNC210, an oral, proprietary, selective negative allosteric modulator of the alpha7 nicotinic acetylcholine receptor for post-traumatic stress disorder.
Health Care · Biotechnology: Pharmaceutical Preparations · 1 employees
ESLA vs NEUP FAQ
Which is bigger, Estrella Immunopharma or Neuphoria Therapeutics?
Neuphoria Therapeutics (NEUP) is larger, with a market capitalization of $18.13M compared with $16.09M for Estrella Immunopharma (ESLA).
Which stock has performed better over the past year, ESLA or NEUP?
ESLA returned -67.88% over the past 12 months, compared with -81.76% for NEUP (price return, excluding dividends). Past performance does not predict future results.
Are Estrella Immunopharma and Neuphoria Therapeutics in the same industry?
Both are in the Health Care sector, but in different industries: Biotechnology: Biological Products (No Diagnostic Substances) for Estrella Immunopharma and Biotechnology: Pharmaceutical Preparations for Neuphoria Therapeutics.